Dr Stephanie Hopley
Apollo Therapeutics Project Director
Steph has 15 years’ experience in drug discovery and development in both big pharma and biotech. She trained as a molecular biologist and was awarded her PhD from the School of Biosciences at The University of Birmingham. She received a Marie Curie postdoctoral fellowship and worked for 2 years at Biovitrum (now Sobi) in Stockholm working on novel ways to produce difficult-to-express proteins. She then joined GlaxoSmithKline in 2004. During her time at GSK, Steph supported large molecule projects across multiple therapeutic areas including oncology, immuno-inflammation and respiratory. Steph then joined Tusk Therapeutics where she worked on several antibody projects in the oncology space. Tusk Therapeutics was acquired by Roche in 2018. Steph has also managed and directed multiple relationships with external partners, both academic and industrial. Steph enjoys working on projects with external partners and has initiated and led several successful collaborations.